Table 1 Patients’ characteristics
From: Impaired skin microvascular endothelial reactivity in critically ill COVID-19 patients
Patients ‘characteristics n (%) or Median [IQR] | Non-COVID-19 bacterial pneumonia N = 11 | COVID-19 N = 32 | P value |
|---|---|---|---|
Age, years | 69 [57–75] | 59 [50–68] | 0.11 |
Men | 7 (63.6) | 21 (65.6) | 1.00 |
BMI, kg/m2 | 22.5 [20.1–28.5] | 26.6 [24.5–34.5] | 0.03 |
SAPS II score | 46 [32–51] | 23 [18.3–30] | < 0.001 |
SOFA score | 4 [2–5.3] | 4 [3, 4] | 0.51 |
Respiratory SOFA score | 2 [2, 3] | 3 [3, 4] | < 0.001 |
Sepsis (sepsis III criteria) | 10 (90) | 32 (100) | 0.94 |
Comorbidities | |||
Active smokers | 5 (45.5) | 4 (12.5) | 0.03 |
Hypertension | 3 (27.3) | 13 (40.6) | 0.49 |
Diabetes mellitus | 2 (18.2) | 6 (18.8) | 1.00 |
Vascular disease | 1 (9.1) | 3 (9.4) | 1.00 |
Cancer/hemopathy | 2 (18.2) | 2 (6.3) | 0.56 |
Time between, days | |||
First symptoms to ICU | 2 [2–7] | 8.5 [6–10] | < 0.001 |
First symptoms to inclusion | 4 [2–7] | 9 [7–10] | < 0.001 |
Respiratory support | |||
Nasal cannula/non-rebreather mask | 10 (90.9) | 7 (21.9) | < 0.001 |
CPAP or BiPAP | 0 (0) | 16 (50) | < 0.001 |
High flow nasal cannula | 1 (9.1) | 25 (78.1) | 0.003 |
Biologicals | |||
Leukocyte count, G/L | 8.63 [1.16–14.59] | 7.745 [4.745–11.3] | 0.90 |
Lymphocyte count, G/L | 1.28 [1.07–1.88] | 0.70 [0.54–0.89] | 0.01 |
Platelet count, G/L | 147[99–266] | 197.5 [171–300.75] | 0.07 |
Creatinine, µmol/L | 71 [52–109] | 62 [53–76] | 0.22 |
Fibrinogen, g/L | 7.09 [4.8–7.79] | 6.76 [5.88–7.68] | 0.67 |
C-reactive protein, mg/L | 240.6 [95.6–302.3] | 73.7 [42.55–121.2] | 0.03 |
Procalcitonin, µg/L | 7.68 [2.8–35.8] | 0.15 [0.1–0.27] | < 0.001 |
Arterial blood gases | |||
pH | 7.42 [7.42–7.44] | 7.48 [7.45–7.51] | 0.002 |
PaCO2, mmHg | 37 [31–38] | 34 [31–37] | 0.22 |
Pa02/FiO2 ratio | 239.5 [165.3–286.8] | 128 [81–157] | 0.002 |
Arterial lactate, mmol/L | 1.6 [1, 2] | 1.3 [1.1–1.7] | 0.45 |